Network Version
AS601245 Data Sheet
| Product Name: | AS601245 |
 |
|---|---|---|
| CAS No.: | 345987-15-7 | |
| Cat. No.: | HY-11010 | |
| MWt: | 372.45 | |
| Formula: | C20H16N6S | |
| Purity : | >98% | |
| Solubility: | DMSO : 10 mg/mL (26.85 mM; Need ultrasonic) | |
| Mechanisms: | Target: Cancer Inflammation/Immunology Neurological Disease | |
| Biological Activity: | ||
|
AS601245 is an orally active, selective, ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC50s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively. AS601245 exhibits 10- to 20-fold selectivity over c-src, CDK2, and c-Raf and more than 50- to 100-fold selectivity over a range of Ser/Thr- and Tyr-protein kinases. Neuroprotective properties[1][2].
IC50 & Target: IC50: 70 nM (hJNK3), 150 nM (hJNK1), 220 nM (hJNK2)[1]
In Vitro: AS601245, an anti-Inflammatory JNK inhibitor, and Clofibrate have a synergistic effect in inducing cell responses and in affecting the gene expression profile in CaCo-2 colon cancer cells [2].
In Vivo: AS601245 (40, 60, and 80 mg/kg; i.p.) provides significant protection against the delayed loss of hippocampal CA1 neurons in a gerbil model of transient global ischemia[1]. AS601245 (0.3-10 mg/kg; p.o.) is a potent inhibitor of LPS-induced TNF-α release in mice[1]. |
||
1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com